|

Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma

RECRUITINGSponsored by Regina Elena Cancer Institute
Actively Recruiting
SponsorRegina Elena Cancer Institute
Started2019-06-18
Est. completion2023-11-11
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05888636

Summary

Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression are involved in MM development. In particular, it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients. Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity. The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

\- Compare Transcriptomics and epigenetic profile

Exclusion Criteria:

* No exclusion criteria

Conditions2

CancerMultiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.